No Data
Hebei Changshan Biochemical Pharmaceutical (300255.SZ): Plans to conclude the "Annual production of 35 tons of heparin series Active Pharmaceutical Ingredient product project" and permanently supplement working capital with the surplus fundraising.
On December 11, Gelonghui reported that Hebei Changshan Biochemical Pharmaceutical (300255.SZ) announced that its fifth Board of Directors' eighteenth meeting and the fifth Supervisory Board's fourteenth meeting on December 11, 2024, reviewed and approved the proposal regarding the conclusion of the fundraising investment project and the permanent supplement of surplus raised funds to working capital, agreeing to conclude the fundraising investment project "Annual production of 35 tons of heparin series Active Pharmaceutical Ingredient products project" and permanently supplement the surplus raised funds to working capital.
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s (SZSE:300255) Top Owners Are Individual Investors With 52% Stake, While 37% Is Held by Insiders
Hebei Changshan Biochemical Pharmaceutical (300255.SZ): Shareholder Yang Minghuan completed a shareholding of 9.1905 million shares.
Globe Link reported on November 26 that Hebei Changshan Biochemical Pharmaceutical (300255.SZ) announced that it recently received a notification letter from Mr. Yang Minghuan regarding the completion of the shareholding plan. The aforementioned shareholding plan has been completed on November 26, 2024, with a reduction of 9,190,457 shares, accounting for 0.99998%.
Changshan Biochemical Pharma Shareholder Trims Stake
Estimating The Intrinsic Value Of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255)
Hebei Changshan Biochemical Pharmaceutical (300255.SZ): The abemaciclib active pharmaceutical ingredient workshop and formulation workshop have been completed, and can be put into commercial production after approval.
On November 1, Changshan Pharmaceutical (300255.SZ) stated on the investor interaction platform that abenpeptide is currently in the evaluation stage of pharmaceutical regulatory authorities and has not yet obtained marketing approval. The company's abenpeptide active pharmaceutical ingredient workshop and formulation workshop have been completed, and can be put into commercial production after approval, with preparations for sales after approval already underway, including team building, marketing strategy, etc.
Investor Optimism Abounds Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255) But Growth Is Lacking
